{"id":"W3092484545","doi":"10.1016/s1470-2045(20)30441-1","title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":587,"is_retracted":false,"has_abstract":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Cilag; Takeda Pharmaceutical Company; AbbVie; National Cancer Institute; Merck Sharp and Dohme; Pharmacyclics; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; Roche","keywords":"Open label; Medicine; Follicular lymphoma; Refractory (planetary science); Oncology; Internal medicine; Phases of clinical research; Follicular phase; Clinical trial; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002526804,0.0002489486,0.0008928779,0.00002964557,0.0001665143,0.000046346,0.0003527804,0.000136235,0.0001178821],"category_scores_gemma":[0.000393605,0.0001277683,0.00005140621,0.0001720813,0.0001027417,0.0001502359,0.0001088024,0.00008927446,0.00003559585],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004287475,"about_ca_system_score_gemma":0.0004133528,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005203185,"about_ca_topic_score_gemma":0.00007259683,"domain_scores_codex":[0.9982566,0.0002445173,0.0003529645,0.0004595875,0.0002343932,0.0004518958],"domain_scores_gemma":[0.9982622,0.0005416351,0.0002576578,0.0004977779,0.0001572827,0.0002834361],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7688298,0.0732818,0.001767502,0.00008116858,0.0007461093,0.000481308,0.001466051,0.000002227927,0.0005082683,0.0002807181,0.02081438,0.1317407],"study_design_scores_gemma":[0.5880129,0.1284346,0.0008670066,0.00003154034,0.0006231972,0.00001295313,0.0001380537,0.0001604064,0.0003567439,0.00002428254,0.2811848,0.0001534461],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9840698,0.0001470744,0.00004348892,0.009165845,0.0003369846,0.004950367,0.0001432622,0.00008547128,0.001057712],"genre_scores_gemma":[0.981441,0.00008507988,0.005595835,0.01046238,0.0009598135,0.0007688676,0.000463335,0.0000554604,0.0001681871],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2603704,"threshold_uncertainty_score":0.5210239,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1386246272526778,"score_gpt":0.3873040580453387,"score_spread":0.2486794307926609,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}